Search

Compugen Ltd

Uždarymo kaina

2.37 0.42

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.33

Max

2.4

Pagrindiniai rodikliai

By Trading Economics

Pajamos

663K

-7M

Pardavimai

426K

2.6M

P/E

Sektoriaus vid.

6.408

55.725

Pelnas, tenkantis vienai akcijai

-0.07

Pelno marža

-269.254

Darbuotojai

75

EBITDA

665K

-7M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+110.97% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.5M

231M

Ankstesnė atidarymo kaina

1.95

Ankstesnė uždarymo kaina

2.37

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-25 23:56; UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, gaining significantly since Friday's close after a recent decline over the past month.

2026-09-25 23:55; UTC

AtriCure Inc is trading modestly higher in after-market hours, remaining above its 20-day moving average despite retracing some initial gains.

2026-09-25 23:55; UTC

Wendy's Co saw modest gains during after-market hours on Friday, continuing its upward movement but remaining below its 20-day moving average.

2026-09-25 23:55; UTC

Lexicon Pharmaceuticals Inc is rising in after-market trading, gaining ground since Friday's close, marking a notable divergence from four consecutive sessions of losses.

2026-09-25 23:55; UTC

Cognizant Technology Solutions Corp is trading modestly higher in after-market hours, reaching a peak return since Friday's close, despite remaining below its 20-day moving average.

2026-09-25 23:51; UTC

Hamilton Beach Brands Holding Co has advanced in after-market trading, significantly above its 20-day moving average and near the upper end of its one-month range.

2026-09-25 23:51; UTC

Social Media

Darden Restaurants Inc reported a rise in sales to $3.2 billion, but net income fell, leading to a decline in stock price in after-market trading.

2026-09-25 23:51; UTC

News

CDW Corp completed its acquisition of Lovelytics, enhancing its Services and Solutions portfolio, as shares advanced in after-market trading.

2026-09-25 23:51; UTC

Krispy Kreme Inc is advancing in after-market trading, showing a notable increase since Friday's close, despite being below its 20-day moving average.

2026-09-25 23:51; UTC

Pacific Biosciences of California Inc is trading lower in after-market hours, reflecting a notable decline since Friday's close and today's sharp loss.

2026-09-25 23:51; UTC

News

AbbVie Inc received FDA approval for Juvmo (Tavapadon), a Parkinson's treatment, contributing to a modest rise in shares during after-market trading.

2026-09-25 23:51; UTC

Southern Co is trading slightly higher in after-market hours, though its price remains below the 20-day moving average after four consecutive lower closes.

2026-09-25 23:51; UTC

Brazil's Industrial Production MoM data release on October 2, 2026, expected to reflect cautious market sentiment amid agricultural sector challenges and external economic pressures.

2026-09-25 23:51; UTC

S&P/Case-Shiller Index Forecasts 2.2% Year-over-Year Home Price Increase Amid Mixed Housing Sentiment and Rising Treasury Yields

2026-09-25 23:51; UTC

South Korea's S&P Global Manufacturing PMI set for October 1 release amid slowing growth and geopolitical tensions impacting market sentiment.

2026-09-25 23:50; UTC

Southern Missouri Bancorp Inc is trading modestly lower in after-market hours, positioned below its 20-day moving average and near the lower end of its one-month range.

2026-09-25 23:50; UTC

Upstart Holdings Inc is trading modestly higher in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

2026-09-25 23:50; UTC

ABM Industries Inc is down in after-market trading, moving from a slight dip to a more pronounced decline since Friday's close.

2026-09-25 23:50; UTC

Arcus Biosciences Inc is trading lower in after-hours, reaching its lowest point of the day and remaining well below its 20-day moving average.

2026-09-25 23:50; UTC

Ambarella Inc is rising in after-market trading, continuing its positive trend and remaining significantly above its 20-day moving average.

2026-09-25 23:50; UTC

Recursion Pharmaceuticals Inc has advanced in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month trading range.

2026-09-25 23:50; UTC

Etsy Inc. has advanced in after-market trading, despite a notable decline from its earlier high and positioning below its 20-day moving average.

2026-09-25 23:50; UTC

Baker Hughes Co is trading modestly higher in after-market hours, showing unusual upward movement despite remaining below its 20-day moving average.

2026-09-25 23:50; UTC

Altria Group Inc is experiencing a slight increase in after-market trading, advancing since Friday's close despite some unusual activity and price retracement.

2026-09-25 23:50; UTC

Medtronic PLC is down in after-market trading, continuing a seven-session trend of lower finishes and remaining significantly below its 20-day moving average.

2026-09-25 23:50; UTC

Tencent Music Entertainment Group declined in after-market trading, continuing a downward trend since Friday's close, despite remaining above its 20-day moving average.

2026-09-25 23:46; UTC

Parker-Hannifin Corp is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

2026-09-25 23:46; UTC

Northern Oil and Gas Inc is trading modestly higher in after-market hours, reaching a peak return since Friday's close, though still below its 20-day moving average.

2026-09-25 23:46; UTC

Modest increase in after-market trading, peak return near 0.9%.

2026-09-25 23:46; UTC

Correlated Moves

Alaska Air Group Inc's shares are trading roughly flat in after-market hours, reflecting routine activity amid slight gains in the Fidelity Enhanced Small Cap Core ETF.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

110.97% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  110.97%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.